RT @laoneill111: First study on resdemivir (anti-viral) in COVID19. Eminent journal (NEJM). Very sick patients on ventilation 13% fatality…
One of the big ones we've been waiting on. An actual anti-viral. Between this and the curves flattening, finally seeing some light.
RT @Nat_anest: В NEJM сегодня опубликовали первый отчёт о применении Ремдесивира 53-и пациентам с тяжёлым течение Covid. Клиническое улучше…
RT @laoneill111: First study on resdemivir (anti-viral) in COVID19. Eminent journal (NEJM). Very sick patients on ventilation 13% fatality…
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
RT @EdBelongia: Some encouraging news on remdesivir. This @NEJM analysis had no control group and is inconclusive, but outcomes were better…
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
RT @ahmedjo70s: يالله يا ولاد خبر كويس أهو..ال Remdesivir بتاع جليد..الشركة اللي عملت أدوية ڤيروس سي..جايب نتيجة كويسة في الحالات الحادة ..…
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
Looking good for your prediction, @michaelzlin
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
Good news! https://t.co/MBwmZWzp1w
RT @laoneill111: First study on resdemivir (anti-viral) in COVID19. Eminent journal (NEJM). Very sick patients on ventilation 13% fatality…
RT @megtirrell: From NEJM article on compassionate use of Gilead’s remdesivir, a breakdown of each patient’s improvement level https://t.co…
В NEJM сегодня опубликовали первый отчёт о применении Ремдесивира 53-и пациентам с тяжёлым течение Covid. Клиническое улучшение было у 68% пациентов. Летальность была 18% среди тех кто был на ИВЛ, и 5% в группе без ИВЛ. Будем ждать РКИ https://t.co/a7O1t
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
RT @ahmedjo70s: يالله يا ولاد خبر كويس أهو..ال Remdesivir بتاع جليد..الشركة اللي عملت أدوية ڤيروس سي..جايب نتيجة كويسة في الحالات الحادة ..…
RT @paomorejon: 📌Compassionate Use of Remdesivir for Patients with Severe #COVIDー19 Improvement in oxygen-support status was observed in…
RT @paomorejon: 📌Compassionate Use of Remdesivir for Patients with Severe #COVIDー19 Improvement in oxygen-support status was observed in…
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
Premiers résultats encourageants de l’antiviral #remdesivir pour le #covid19, en particulier et y compris dans les cas sévères sous ventilation mécanique @NEJM
Pts hospitalized for severe #COVID-19 who were treated with compassionate-use remdesivir, clinical improvement was observed in 36 of 53 patients (68%) @NEJM https://t.co/ynRPozrUHb
RT @CovidFor: ... treated with compassionate-use remdesivir, clinical improvement was observed in 36 of 53 patients (68%) https://t.co/Rjn1…
RT @accpinfdprn: 📄 New today from @NEJM on @GileadSciences’s remdesivir for #COVID19 📲 https://t.co/LPlhryLTAW No comparator. 68% had cl…
Some encouraging news on remdesivir. This @NEJM analysis had no control group and is inconclusive, but outcomes were better than expected with no treatment. We will soon have more definitive results from 2 randomized trials in patients with severe and mild
دراسة على علاج COVID 19 نتائج جيدة لعلاج الحالات المتقدمة لڤيروس كورونا المستجد باستخدام دواء remdesivir الدراسة نشرت اليوم https://t.co/leZVQhwgGl
Remdesivir for COVID19 patients with low oxygen saturation: a faint ray of sunshine based on a small sample, open-label study. https://t.co/zNG1vPjyoz https://t.co/Jaz64471Ne
#Remdesivir by $GILD, FYI!
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
RT @laoneill111: First study on resdemivir (anti-viral) in COVID19. Eminent journal (NEJM). Very sick patients on ventilation 13% fatality…
$GILD $BCRX https://t.co/N3hDyg1QaJ No control group though....
Reference to Remdesivir data in @NEJM today: https://t.co/a7nR8c4Vpi Correct and Gilead also agrees. Hence they are asking everyone to be patient & wait for clinical trial data beyond compassionate use. I.E. don’t make this the next HCQ. https://t.co/
@matthewherper How would you define this? Is it a 61 patient case- report? https://t.co/LTpwpzC9oL
RT @GermHunterMD: Here is a study. It is uncontrolled. It is not good. What are we doing here?
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
RT @laoneill111: First study on resdemivir (anti-viral) in COVID19. Eminent journal (NEJM). Very sick patients on ventilation 13% fatality…
... treated with compassionate-use remdesivir, clinical improvement was observed in 36 of 53 patients (68%) https://t.co/Rjn194dc6x
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
RT @laoneill111: First study on resdemivir (anti-viral) in COVID19. Eminent journal (NEJM). Very sick patients on ventilation 13% fatality…
RT @laoneill111: First study on resdemivir (anti-viral) in COVID19. Eminent journal (NEJM). Very sick patients on ventilation 13% fatality…
RT @megtirrell: From NEJM article on compassionate use of Gilead’s remdesivir, a breakdown of each patient’s improvement level https://t.co…
First study on resdemivir (anti-viral) in COVID19. Eminent journal (NEJM). Very sick patients on ventilation 13% fatality (untreated would be much higher) overall 68% improvement. No control group, but given severity of patients results encouraging. https
@RobertoBurioni @WRicciardi @ProfLopalco
Compassionate Use of Remdesivir for Patients with Severe Covid-19 | NEJM #COVIDー19 #Gilead https://t.co/8MUxe34TLb?
RT @AndyBiotech: NEJM report on compassionate use of Remdesivir for 53 patients with severe #COVID19 https://t.co/gL0QKtw39L … 36/53 (68%)…
But in the meantime, exercise judgment and use what appears to work. Don't wait for an A/B test.
#wow #remdesivir if we could only get into a #Clinicaltrial @GileadSciences https://t.co/QwPpcBY2t8
No obvious toxic effects on this small number base. Still need to have randomized controlled trial's results by the later part of April which is still going on in China. Hopefully it would not have been rigged.
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
Looking forward to RCT results for remdesivir. Here is some early, uncontrolled data: https://t.co/AO40QkxFEL
On remdesivir & compassionate use #scicomm
This
RT @ahmedjo70s: يالله يا ولاد خبر كويس أهو..ال Remdesivir بتاع جليد..الشركة اللي عملت أدوية ڤيروس سي..جايب نتيجة كويسة في الحالات الحادة ..…
RT @ahmedjo70s: يالله يا ولاد خبر كويس أهو..ال Remdesivir بتاع جليد..الشركة اللي عملت أدوية ڤيروس سي..جايب نتيجة كويسة في الحالات الحادة ..…
🌍 Remdesivir (uso compasivo) en #COVID19 grave (SO2 <94%): 53 pctes (75%H, 64a prom, sgto 18d prom) -68% pctes mejoró O2 (57% en VMI y 75% en ECMO) -84% mejoría clínica (escala de 6ptos o alta) -Mortalidad 13% (previa 66% en pctes graves) -60% ef advers
RT @ahmedjo70s: يالله يا ولاد خبر كويس أهو..ال Remdesivir بتاع جليد..الشركة اللي عملت أدوية ڤيروس سي..جايب نتيجة كويسة في الحالات الحادة ..…
RT @ahmedjo70s: يالله يا ولاد خبر كويس أهو..ال Remdesivir بتاع جليد..الشركة اللي عملت أدوية ڤيروس سي..جايب نتيجة كويسة في الحالات الحادة ..…
RT @accpinfdprn: 📄 New today from @NEJM on @GileadSciences’s remdesivir for #COVID19 📲 https://t.co/LPlhryLTAW No comparator. 68% had cl…
RT @GlobalMedEd: #Remdesevir found helpful in severe COVID 19 patients. https://t.co/zL1iKd9Jz9 #nursepractitioner #mh #mhchat #primarycar…
RT @ahmedjo70s: يالله يا ولاد خبر كويس أهو..ال Remdesivir بتاع جليد..الشركة اللي عملت أدوية ڤيروس سي..جايب نتيجة كويسة في الحالات الحادة ..…
RT @ahmedjo70s: يالله يا ولاد خبر كويس أهو..ال Remdesivir بتاع جليد..الشركة اللي عملت أدوية ڤيروس سي..جايب نتيجة كويسة في الحالات الحادة ..…
RT @ahmedjo70s: يالله يا ولاد خبر كويس أهو..ال Remdesivir بتاع جليد..الشركة اللي عملت أدوية ڤيروس سي..جايب نتيجة كويسة في الحالات الحادة ..…
RT @megtirrell: From NEJM article on compassionate use of Gilead’s remdesivir, a breakdown of each patient’s improvement level https://t.co…
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
$GILD #COVIDー19 As the world awaits RCT results, cases of Remdesivir compassionate use show signs that hope may be warranted... https://t.co/TuxPm0git3
RT @paomorejon: 📌Compassionate Use of Remdesivir for Patients with Severe #COVIDー19 Improvement in oxygen-support status was observed in…
#Remdesevir found helpful in severe COVID 19 patients. https://t.co/zL1iKd9Jz9 #nursepractitioner #mh #mhchat #primarycare #familymedicine #anxiety #mentalhealth #medicine #COVID19 #Gilead https://t.co/OtZxNDsEBC
Compassionate Use of Remdesivir for Patients with Severe Covid-19 | NEJM https://t.co/BuDQdLpwqF
Acaba de salir el primer trabajo sobre Remdesivir en #COVID19 en @NEJM. Se trata de los datos de un programa de uso compasivo de este medicamento https://t.co/LTpwpzC9oL https://t.co/wLIJgI4qxX
RT @megtirrell: From NEJM article on compassionate use of Gilead’s remdesivir, a breakdown of each patient’s improvement level https://t.co…
RT @accpinfdprn: 📄 New today from @NEJM on @GileadSciences’s remdesivir for #COVID19 📲 https://t.co/LPlhryLTAW No comparator. 68% had cl…
#remdesivir works
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
RT @FurnoX: Encouraging Remdesivir data https://t.co/ty4BBucpG3
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
#Hope #COVIDー19 #SafeAtHome @CedarsSinai @angelesclinic
RT @ahmedjo70s: يالله يا ولاد خبر كويس أهو..ال Remdesivir بتاع جليد..الشركة اللي عملت أدوية ڤيروس سي..جايب نتيجة كويسة في الحالات الحادة ..…
RT @AndyBiotech: NEJM report on compassionate use of Remdesivir for 53 patients with severe #COVID19 https://t.co/gL0QKtw39L … 36/53 (68%)…
RT @ahmedjo70s: يالله يا ولاد خبر كويس أهو..ال Remdesivir بتاع جليد..الشركة اللي عملت أدوية ڤيروس سي..جايب نتيجة كويسة في الحالات الحادة ..…
$GILD compassionate use data encouraging (caveat for low N and lack of control group). 68% (36/53) exhibit clinical improvement by oxygen support class. 53% (17/30 ) receiving mechanical vent were extubated after 10 day remdesivir regimen https://t.co/Jq3I
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
RT @jsmadero: Uso abierto de remdesivir en pac con enfermedad grave por Covid-19. Mortalidad 18% en pac con ventilación mecánica. Compassi…
RT @accpinfdprn: 📄 New today from @NEJM on @GileadSciences’s remdesivir for #COVID19 📲 https://t.co/LPlhryLTAW No comparator. 68% had cl…
RT @EricTopol: Big for #COVID19 therapy: the compassionate use results for remdesivir in 53 patients looks very encouraging, especially in…
Uso abierto de remdesivir en pac con enfermedad grave por Covid-19. Mortalidad 18% en pac con ventilación mecánica. Compassionate Use of Remdesivir for Patients with Severe Covid-19 | NEJM https://t.co/39N4ZTc0AW
RT @OncIDPharmd: Some remdesivir data! My quick take is that mortality seems to be lower than expected, but based on Figure 2 (improvement…